NCT00672243 - Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2009

Conditions

GlioblastomaGliosarcoma

Interventions

DRUG

Erlotinib + sirolimus

Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.

Trial Locations (1)

27710

Duke University Health System, Durham